{"id":"W4206949196","doi":"10.1182/blood-2019-131217","title":"Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Monocytosis; Myelofibrosis; Refractory (planetary science); Internal medicine; Ruxolitinib; Phases of clinical research; Myeloid; Oncology; Regimen; Gastroenterology; Clinical trial; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003066192,0.001370768,0.001507089,0.0003088285,0.0003925893,0.000807062,0.0006067617,0.001399482,0.003813499],"category_scores_gemma":[0.001356376,0.0003378079,0.001287524,0.0002424369,0.0006941602,0.0008299106,0.0002887446,0.002123026,0.0006889973],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006695521,"about_ca_system_score_gemma":0.001279974,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004788403,"about_ca_topic_score_gemma":0.00172804,"domain_scores_codex":[0.9993497,0.0003350351,0.00004683481,0.0001017502,0.00005192464,0.0001148072],"domain_scores_gemma":[0.9990326,0.0002119812,0.0001577199,0.00008015402,0.00007204646,0.0004454889],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7042089,0.05697919,0.01428492,0.00139099,0.002436472,0.0005224292,0.0003471729,0.004180531,0.04775127,0.0005637249,0.01133697,0.1559974],"study_design_scores_gemma":[0.5832721,0.3862187,0.01847608,0.00007509013,0.001230856,0.0004623318,0.00005721198,0.001295414,0.00401284,0.0005284196,0.004329761,0.00004108628],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9811597,0.003821308,0.001065276,0.001432884,0.0001702653,0.004891908,0.004018557,0.0001579248,0.003282116],"genre_scores_gemma":[0.9806769,0.001973525,0.002480019,0.001703009,0.0002469431,0.004500754,0.006049993,0.00002766793,0.002341222],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003813499,"threshold_uncertainty_score":0.0162158,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02153929252051434,"score_gpt":0.3020193437126692,"score_spread":0.2804800511921549,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}